Current optimal pharmacologic therapies for overactive bladder

References

• Haylen BT, Freeman RM, Swift SE, et al. An international Urogynecological Association (Iuga)/international Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. Neurourol Urodyn. 2011;30(1):2–12. doi: 10.1002/nau.21036
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167–178. doi: 10.1002/nau.10052
   PubMed Web of Science ®Google Scholar
• Guralnick ML, Grimsby G, Liss M, et al. Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity. Int Urogynecol J. 2010;21:325–329. doi: 10.1007/s00192-009-1030-7
   PubMed Web of Science ®Google Scholar
• Haylen BT, Chetty N, Logan V, et al. Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity? Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:123–128. doi: 10.1007/s00192-006-0165-z
   PubMedGoogle Scholar
• Drake MJ, Harvey IJ, Gillespie JI, et al. Localized contractions in the normal human bladder and in urinary urgency. BJU Int. 2005;95:1002–1005. doi: 10.1111/j.1464-410X.2005.05455.x
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Honda K, Nomiya M, et al. Defining overactive bladder as hypersensitivity. Neurourol Urodyn. 2007;26(6 Suppl):904–907. doi: 10.1002/nau.20482
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314. doi: 10.1016/j.eururo.2006.09.019
   PubMed Web of Science ®Google Scholar
• Malmsten UG, Molander U, Peeker R, et al. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years. Eur Urol. 2010;58:149–156. doi: 10.1016/j.eururo.2010.03.014
   PubMed Web of Science ®Google Scholar
• Wang HJ, Kuo HC. Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice. Tzu Chi Med J. 2022;34:441–447. doi: 10.4103/tcmj.tcmj_264_20
   PubMed Web of Science ®Google Scholar
• Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202:558–563. doi: 10.1097/JU.0000000000000309
   PubMed Web of Science ®Google Scholar
• Nambiar AK, Arlandis S, Bø K, et al. European Association of urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82:49–59. doi: 10.1016/j.eururo.2022.01.045
   PubMed Web of Science ®Google Scholar
• Ouslander JG, Wood AJJ. Management of overactive bladder. N Engl J Med. 2004;350(8):786–799. doi: 10.1056/NEJMra032662
   PubMed Web of Science ®Google Scholar
• Thüroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Eur Urol. 2011;59(3):387–400. doi: 10.1016/j.eururo.2010.11.021
   PubMed Web of Science ®Google Scholar
• Nunzio C DE, Nacchia A, Gravina C, et al. Adverse events related to antimuscarinics and beta-3-agonist: “real-life” data from the eudra-vigilance database. Minerva Urol Nephrol. 2022;74:761–779. doi: 10.23736/S2724-6051.22.04849-2
   PubMedGoogle Scholar
• Pradhan T, Dhamala JN, Yadav SK, et al. Patient perception of bladder condition after treatment with solifenacin and tolterodine in overactive bladder patients. J Nepal Health Res Counc. 2023;20(3):750–754. doi: 10.33314/jnhrc.v20i3.4366
   PubMedGoogle Scholar
• Warli SM, Firsty NN, Natalia D, et al. Urodynamic parameter improvements after mirabegron vs. antimuscarinics agents in non-neurogenic overactive bladder: a systematic review and meta-analysis of treatment effect. Eur Rev Med Pharmacol Sci. 2023;27(9):3864–3876. doi: 10.26355/eurrev_202305_32292
   PubMed Web of Science ®Google Scholar
• Gray SL, Hanlon JT. Anticholinergic medication use and dementia: latest evidence and clinical implications. Ther Adv Drug Saf. 2016;7(5):217–224. doi: 10.1177/2042098616658399
   PubMedGoogle Scholar
• Vouri SM, Kebodeaux CD, Stranges PM, et al. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2017;69:77–96. doi: 10.1016/j.archger.2016.11.006
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Talwar A, Aparasu RR. Anticholinergic medications and risk of dementia in older adults: where are we now? Expert Opin Drug Saf. 2020;19(10):1251–1267. doi: 10.1080/14740338.2020.1811227
   PubMed Web of Science ®Google Scholar
• Dengler KL, High RA, Moga DC, et al. Overactive bladder and cognitive mpairment: the American Urogynecologic Society and pelvic floor disorders research Foundation state-of-the-science conference summary report. Urogynecology. 2023;29(1S Suppl 1):S1–S19. doi: 10.1097/SPV.0000000000001272
   PubMedGoogle Scholar
• Kuo HC. How to choose appropriate medication for overactive bladder: findings from the largest integrated clinical trial database analysis of mirabegron studies. Tzu Chi Med J. 2022;34:23–28.
   PubMed Web of Science ®Google Scholar
• Nambiar AK, Bosch R, Cruz F, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2018;73(4):596–609. doi: 10.1016/j.eururo.2017.12.031
   PubMed Web of Science ®Google Scholar
• Birder LA, Nealen ML, Kiss S, et al. Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci. 2002;22:8063–8070. doi: 10.1523/JNEUROSCI.22-18-08063.2002
   PubMed Web of Science ®Google Scholar
• Aizawa N, Igawa Y, Nishizawa O, et al. Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn. 2010;29:771–776. doi: 10.1002/nau.20826
   PubMed Web of Science ®Google Scholar
• Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321:642–647. doi: 10.1124/jpet.106.115840
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–1458. doi: 10.1007/s00192-013-2042-x
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305. doi: 10.1016/j.eururo.2012.10.048
   PubMed Web of Science ®Google Scholar
• Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol. 2017;9(6):137–154. doi: 10.1177/1756287217702797
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119–128. doi: 10.1016/j.eururo.2019.09.024
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–632. doi: 10.1111/ijcp.12194
   PubMed Web of Science ®Google Scholar
• Takahashi S, Mishima Y, Kuroishi K, et al. Efficacy of mirabegron, a β3-adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int J Urol. 2022;29(1):7–15. doi: 10.1111/iju.14700
   PubMed Web of Science ®Google Scholar
• Wagg A, Staskin D, Engel E, et al. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211–220. doi: 10.1016/j.eururo.2019.10.002.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34(7):685–692. doi: 10.1002/nau.22645
   PubMed Web of Science ®Google Scholar
• Sartori LGF, Nunes BM, Farah D, et al. Mirabegron and anticholinergics in the treatment of overactive bladder syndrome: a meta-analysis. Rev Bras Ginecol Obstet. 2023;45:337–346. doi: 10.1055/s-0043-1770093
   PubMedGoogle Scholar
• Kennelly M, Wielage R, Shortino D, et al. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context. 2022;11:2022-4–2. doi: 10.7573/dic.2022-4-2
   Google Scholar
• Kitta T, Chiba H, Kon M, et al. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder. J Pediatr Urol. 2022;18(5):563–569. doi: 10.1016/j.jpurol.2022.07.012
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783–790. doi: 10.1016/j.eururo.2017.12.022
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, et al. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020;125:709–717. doi: 10.1111/bju.15020
   PubMed Web of Science ®Google Scholar
• Staskin D, Frankel J, Varano S, et al. Vibegron for the treatment of patients with dry and wet overactive bladder: a subgroup analysis from the EMPOWUR trial. Int J Clin Pract. 2022;2022:6475014. doi: 10.1155/2022/6475014
   PubMed Web of Science ®Google Scholar
• Staskin D, Frankel J, Varano S, et al. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J Urol. 2021;205(5):1421–1429. doi: 10.1097/JU.0000000000001574
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Rovner ES, Kennelly MJ, et al. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder. BMC Urol. 2023;23(1):64. doi: 10.1186/s12894-023-01240-7
   PubMed Web of Science ®Google Scholar
• Onur R, Bayrak Ö, Coşkun B, et al. Clinical preferences and treatment attitudes among urologists, gynecologists, and geriatricians: an independent online questionnaire survey for comparison of treatment choices in the management of overactive bladder. Neurourol Urodyn. 2022;41(8):1914–1923. doi: 10.1002/nau.25050
   PubMed Web of Science ®Google Scholar
• Kay GG, Abou-Donia MB, WS M Jr, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53:2195–2201. doi: 10.1111/j.1532-5415.2005.00537.x
   PubMed Web of Science ®Google Scholar
• Tsubouchi K, Arima H, Abe M, et al. Effect of pharmacotherapy for overactive bladder on the incidence of and factors related to urinary tract infection: a systematic review and meta-analysis. J Urol. 2023;209:665–674. doi: 10.1097/JU.0000000000003209
   PubMed Web of Science ®Google Scholar
• Yeowell G, Smith P, Nazir J, et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11):e021889. doi: 10.1136/bmjopen-2018-021889
   PubMed Web of Science ®Google Scholar
• Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20(1):109. doi: 10.1186/s12877-020-1474-7
   PubMed Web of Science ®Google Scholar
• Johnson TM 2nd, Walker D, Lockefeer A, et al. Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States medicare population. Neurourol Urodyn. 2022;41:1872–1889. doi: 10.1002/nau.25040.
   PubMed Web of Science ®Google Scholar
• Welk B. The differential risk of mortality among users of overactive bladder anticholinergic medications and β3 agonists. Eur Urol Focus. 2023;9:168–171.
   PubMedGoogle Scholar
• Mostafaei H, Salehi-Pourmehr H, Jilch S, et al. Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis. Eur Urol Focus. 2022;8(4):1072–1089. doi: 10.1016/j.euf.2021.08.011
   PubMedGoogle Scholar
• Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–333. doi: 10.1016/j.eururo.2018.03.020
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony). Eur Urol. 2015;67(3):577–588. doi: 10.1016/j.eururo.2014.02.012
   PubMed Web of Science ®Google Scholar
• Gratzke C, Chapple C, Mueller ER, et al. Efficacy and safety of combination pharmacotherapy for patients with overactive bladder: a rapid evidence assessment. Eur Urol. 2019;76:767–779. doi: 10.1016/j.eururo.2019.07.010
   PubMed Web of Science ®Google Scholar
• Wang CC, Jiang YH, Kuo HC. Efficacy and adherence of fexibly aAdding on a second antimuscarinic agent for patients with refractory overactive bladder. Low Urin Tract Symptoms. 2017;9:27–32. doi: 10.1111/luts.12103
   PubMed Web of Science ®Google Scholar
• Mueller ER, van Maanen R, Chapple C, et al. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourol Urodyn. 2019;38(2):779–792. doi: 10.1002/nau.23919
   PubMed Web of Science ®Google Scholar
• Kuo YC, Kuo HC. Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients. Tzu Chi Med J. 2023;35(1):62–68. doi: 10.4103/tcmj.tcmj_209_21
   PubMed Web of Science ®Google Scholar
• Lee SH, Chung BH, Kim SJ, et al. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis. 2011;14(4):320–325. doi: 10.1038/pcan.2011.22
   PubMed Web of Science ®Google Scholar
• Liao CH, Kuo YC, Kuo HC. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms. Urology. 2013;81(5):1030–1033. doi: 10.1016/j.urology.2013.01.018
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Gong J, et al. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int. 2012;109:1831–1840. doi: 10.1111/j.1464-410X.2011.10624.x
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803. doi: 10.1016/j.juro.2011.01.074
   PubMed Web of Science ®Google Scholar
• Herschorn S, McVary KT, Cambronero Santos J, et al. Mirabegron vs placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a safety analysis from the randomized, phase 4 PLUS study. Urology. 2021;147:235–242. doi: 10.1016/j.urology.2020.09.040
   PubMed Web of Science ®Google Scholar
• Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. Low Urin Tract Symptoms. 2019;11:177–181. doi: 10.1111/luts.12262
   PubMed Web of Science ®Google Scholar
• Lombardo R, Tubaro A, Burkhard F. Nocturia: the complex role of the heart, kidneys, and bladder. Eur Urol Focus. 2020;6:534–536.
   PubMedGoogle Scholar
• Di Bello F, Napolitano L, Abate M, et al. Nocturia and obstructive sleep apnea syndrome: a systematic review. Sleep Med Rev. 2023;69:101787. doi: 10.1016/j.smrv.2023.101787
   PubMed Web of Science ®Google Scholar
• Weiss JP, Everaert K. Management of nocturia and nocturnal polyuria. Urology. 2019;133S:24–33. doi: 10.1016/j.urology.2019.09.022
   PubMedGoogle Scholar
• Griffiths D, Derbyshire S, Stenger A, et al. Brain control of normal and overactive bladder. J Urol. 2005;174(5):1862–1867. doi: 10.1097/01.ju.0000177450.34451.97
   PubMed Web of Science ®Google Scholar
• Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016;263(12):2555–2564. doi: 10.1007/s00415-016-8212-2
   PubMed Web of Science ®Google Scholar
• Chang TL, Chen SF, Kuo HC. Surgical outcome of male patients with chronic central nervous system disorders and voiding dysfunction due to bladder outlet obstruction. Int Urol Nephrol. 2022;54:2511–2519.
   PubMed Web of Science ®Google Scholar
• Pettersen R, Stien R, Wyller TB. Post-stroke urinary incontinence with impaired awareness of the need to void: clinical and urodynamic features. BJU Int. 2007;99(5):1073–1077. doi: 10.1111/j.1464-410X.2007.06754.x
   PubMed Web of Science ®Google Scholar
• Bapir R, Bhatti KH, Eliwa A, et al. Efficacy of overactive neurogenic bladder treatment: a systematic review of randomized controlled trials. Arch Ital Urol Androl. 2022;94(4):492–506. doi: 10.4081/aiua.2022.4.492
   PubMedGoogle Scholar
• Chen SF, Kuo HC. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Low Urin Tract Symptoms. 2019;11:O53–O58. doi: 10.1111/luts.12215
   PubMed Web of Science ®Google Scholar
• Jiang YH, Chen SF, Kuo HC. Role of videourodynamic study in precision diagnosis and treatment for lower urinary tract dysfunction. Tzu Chi Med J. 2020;32(2):121–130. doi: 10.4103/tcmj.tcmj_178_19
   Web of Science ®Google Scholar
• Jiang YH, Wang CC, Kuo HC, et al. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. Plos One. 2018;13(2):e0190704. doi: 10.1371/journal.pone.0190704
   PubMed Web of Science ®Google Scholar
• Hsiao SM, Lin HH, Kuo HC. Videourodynamic studies of women with voiding dysfunction. Sci Rep. 2017;7(1):6845. doi: 10.1038/s41598-017-07163-2
   PubMedGoogle Scholar
• Athanasopoulos A, Chapple C, Fowler C, et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol. 2011;60(1):94–105. doi: 10.1016/j.eururo.2011.03.054
   PubMed Web of Science ®Google Scholar
• Johnson TM 2nd, Goode PS, Hammontree L, et al. An exploratory analysis of tamsulosin for overactive bladder (OAB) in men with varying voiding symptom burden. Urology. 2021;153:42–48. doi: 10.1016/j.urology.2021.01.022
   PubMed Web of Science ®Google Scholar
• Liao CH, Kuo HC. Mirabegron 25 mg monotherapy is safe but less effective in male patients with overactive bladder and bBladder outlet obstruction. Urology. 2018;117:115–119. doi: 10.1016/j.urology.2018.03.038
   PubMed Web of Science ®Google Scholar
• Yang Z, Dolber PC, Fraser MO. Differential vulnerabilities of urethral afferents in diabetes and discovery of a novel urethra-to-urethra reflex. Am J Physiol Renal Physiol. 2010;298:F118–124. doi: 10.1152/ajprenal.00281.2009
   PubMed Web of Science ®Google Scholar
• McLennan MT, Melick C, Bent AE. Urethral instability: clinical and urodynamic characteristics. Neurourol Urodyn. 2001;20(6):653–660. doi: 10.1002/nau.1016
   PubMed Web of Science ®Google Scholar
• Birder LA, de Wachter S, Gillespie J, et al. Urethral sensation: basic mechanisms and clinical expressions. Int J Urol. 2014;21(Suppl 1):13–16. doi: 10.1111/iju.12349
   PubMedGoogle Scholar
• Woock JP, Yoo PB, Grill WM. Intraurethral stimulation evokes bladder responses via 2 distinct reflex pathways. J Urol. 2009;182(1):366–373. doi: 10.1016/j.juro.2009.02.110
   PubMed Web of Science ®Google Scholar
• Yung KK, Cheung RYK, Wan OYK, et al. Treatment outcome of women with urodynamic mixed urinary incontinence: an observational study. Int Urogynecol J. 2023;34(3):665–673. doi: 10.1007/s00192-022-05097-6
   PubMed Web of Science ®Google Scholar
• Chiba H, Mitsui T, Kitta T, et al. The role of serotonergic mechanism in the rat prefrontal cortex for controlling the micturition reflex: an in vivo microdialysis study. Neurourol Urodyn. 2016;35(8):902–907. doi: 10.1002/nau.22843
   PubMed Web of Science ®Google Scholar
• Alberti C. Coadministration of low-dose serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine with α 2-adrenoceptor blockers to treat both female and male mild-to-moderate stress urinary incontinence (SUI). G Chir. 2013;34:189–194. doi: 10.11138/gchir/2013.34.7.189
   PubMedGoogle Scholar
• Rahnama’i MS, Marcelissen T, Geavlete B, et al. Current management of post-radical prostatectomy urinary incontinence. Front Surg. 2021;8:647656. doi: 10.3389/fsurg.2021.647656
   PubMed Web of Science ®Google Scholar
• Kotecha P, Sahai A, Malde S. Use of duloxetine for postproatectomy stress urinary incontinence: a systematic review. Eur Urol Focus. 2021;7:618–628. doi: 10.1016/j.euf.2020.06.007
   PubMedGoogle Scholar
• Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ. 2017;189(5):E194–E203. doi: 10.1503/cmaj.151104
   PubMed Web of Science ®Google Scholar
• Tyagi P, Tyagi V, Qu X, et al. Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population. Int Urol Nephrol. 2014;46(5):871–877. doi: 10.1007/s11255-013-0621-x
   PubMed Web of Science ®Google Scholar
• Suskind AM. The aging overactive bladder: a review of aging-related changes from the brain to the bladder. Curr Bladder Dysfunct Rep. 2017;12(1):42–47. doi: 10.1007/s11884-017-0406-7
   PubMed Web of Science ®Google Scholar
• Suskind AM, Quanstrom K, Zhao S, et al. Overactive bladder is strongly associated with frailty in older individuals. Urology. 2017;106:26–31. doi: 10.1016/j.urology.2017.03.058
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–1774. doi: 10.1111/j.1464-410X.2012.11023.x
   PubMed Web of Science ®Google Scholar
• Liao CH, Wang CC, Jiang YH. Intravesical onabotulinumtoxinA injection for overactive bladder patients with frailty, medical comorbidities or prior lower urinary tract surgery. Toxins (Basel). 2016;8(4):91. doi: 10.3390/toxins8040091
   PubMed Web of Science ®Google Scholar
• Liao CH, Kuo HC. Practical aspects of botulinum toxin-A treatment in patients with overactive bladder syndrome. Int Neurourol J. 2015;19(4):213–219. doi: 10.5213/inj.2015.19.4.213
   PubMed Web of Science ®Google Scholar
• Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653–680. doi: 10.1152/physrev.00030.2012
   PubMed Web of Science ®Google Scholar
• Grundy L, Caldwell A, Brierley SM. Mechanisms underlying overactive bladder and interstitial cystitis/painful bladder syndrome. Front Neurosci. 2018;12:931. doi:10.3389/fnins.2018.00931
   PubMed Web of Science ®Google Scholar
• Keay SK, Birder LA, Chai TC. Evidence for bladder urothelial pathophysiology in functional bladder disorders. Biomed Res Int. 2014;2014:865463. doi: 10.1155/2014/865463
   PubMed Web of Science ®Google Scholar
• Brierley SM, Linden DR. Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat Rev Gastroenterol Hepatol. 2014;11(10):611–627. doi: 10.1038/nrgastro.2014.103
   PubMed Web of Science ®Google Scholar
• Wang CC, Kuo HC. Urothelial dysfunction and chronic inflammation in diabetic patients with overactive bladder. Low Urin Tract Symptoms. 2017;9:151–156. doi: 10.1111/luts.12126
   PubMed Web of Science ®Google Scholar
• Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn. 2010;29:112–115. doi: 10.1002/nau.20796
   PubMed Web of Science ®Google Scholar
• Birder LA, Wolf-Johnston AS, Sun Y, et al. Alteration in TRPV1 and muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiol (Oxf). 2013;207(1):123–129. doi: 10.1111/j.1748-1716.2012.02462.x
   PubMed Web of Science ®Google Scholar
• Cerruto MA, Asimakopoulos AD, Artibani W, et al. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity. Urol Int. 2012;89(1):1–8. doi: 10.1159/000339251
   PubMed Web of Science ®Google Scholar
• Jiang YH, Yu WR, Kuo HC. Therapeutic effect of botulinum toxin a on sensory bladder disorders-from bench to bedside. Toxins (Basel). 2020;2:166. doi: 10.3390/toxins12030166
   Google Scholar
• Jiang YH, Jhang JF, Kuo HC. The clinical application of intravesical botulinum toxin a injection in patients with overactive bladder and interstitial cystitis. Tzu Chi Med J. 2023;35:31–37.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Boedtkjer DB, Forman A. The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction. Ther Adv Urol. 2017;9(1):11–27. doi: 10.1177/1756287216675778
   PubMed Web of Science ®Google Scholar
• Greenland JE, Brading AF. Urinary bladder blood flow changes during the micturition cycle in a conscious pig model. J Urol. 1996;156:1858–1861. doi: 10.1016/S0022-5347(01)65553-8
   PubMed Web of Science ®Google Scholar
• Greenland JE, Brading AF. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001;165(1):245–248. doi: 10.1097/00005392-200101000-00072
   PubMed Web of Science ®Google Scholar
• Ponholzer A, Temml C, Wehrberger C, et al. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol. 2006;50(3):581–586. doi: 10.1016/j.eururo.2006.01.031
   PubMed Web of Science ®Google Scholar
• Papaefstathiou E, Gatsos S, Tigkiropoulos K, et al. Role of pelvic ischemia in human lower urinary tract symptoms and sexual function among patients with common iliac artery obstruction undergoing revascularization surgery. Int Neurourol J. 2023;27(2):129–138. doi: 10.5213/inj.2346028.014
   PubMed Web of Science ®Google Scholar
• Jiang YH, Jhang JF, Wu YH, et al. Investigating urine biomarkers in detrusor underactivity and detrusor overactivity with detrusor underactivity patients. Biomedicines. 2023;11(4):1191. doi: 10.3390/biomedicines11041191
   PubMed Web of Science ®Google Scholar
• Sawada N, Nomiya M, Hood B, et al. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol. 2013;64(4):664–671. doi: 10.1016/j.eururo.2013.06.043
   PubMed Web of Science ®Google Scholar
• Goi Y, Tomiyama Y, Nomiya M, et al. Effects of silodosin, a selective α1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction. J Urol. 2013;190(3):1116–1122. doi: 10.1016/j.juro.2013.03.110
   PubMed Web of Science ®Google Scholar
• Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol. 2015;22(1):40–46. doi: 10.1111/iju.12652
   PubMed Web of Science ®Google Scholar
• Joseph S, Maria SA, Peedicayil J. Drugs currently undergoing preclinical or clinical trials for the treatment of overactive bladder: a review. Curr Ther Res Clin Exp. 2022;96:100669. doi: 10.1016/j.curtheres.2022.100669
   PubMed Web of Science ®Google Scholar
• Burgio KL, Kraus SR, Johnson TM 2nd, et al. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med. 2020;180:411–419. doi: 10.1001/jamainternmed.2019.6398
   PubMed Web of Science ®Google Scholar
• Liu HT, Tyagi P, Chancellor MB, et al. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int. 2009;104:1476–1481. doi: 10.1111/j.1464-410X.2009.08675.x
   PubMed Web of Science ®Google Scholar
• Chung SD, Liu HT, Lin H, et al. Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn. 2011;30(3):417–420. doi: 10.1002/nau.20938
   PubMed Web of Science ®Google Scholar
• Liu HT, Shie JH, Chen SH, et al. Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome. Urology. 2012;80:225.e13–18. doi: 10.1016/j.urology.2012.01.047
   PubMed Web of Science ®Google Scholar
• Tyagi P, Barclay D, Zamora R, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol. 2010;42(3):629–635. doi: 10.1007/s11255-009-9647-5
   PubMed Web of Science ®Google Scholar
• Jiang YH, Jhang JF, Hsu YH, et al. Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. Sci Rep. 2021;11(1):914. doi: 10.1038/s41598-020-80131-5
   PubMed Web of Science ®Google Scholar
• Kwon WA, Ahn SH, Oh TH, et al. Effect of low-dose triple therapy using gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug for overactive bladder symptoms in patients with bladder pain syndrome. Int Neurourol J. 2013;17(2):78–82. doi: 10.5213/inj.2013.17.2.78
   PubMed Web of Science ®Google Scholar
• Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin a. Nat Rev Urol. 2015;12(9):519–533. doi: 10.1038/nrurol.2015.193
   PubMed Web of Science ®Google Scholar
• Jo JK, Kim KN, Kim DW, et al. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. World J Urol. 2018;36(2):305–317. doi: 10.1007/s00345-017-2121-6
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liu HT, Chuang YC, et al. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65(6):1117–1124. doi: 10.1016/j.eururo.2014.01.036
   PubMed Web of Science ®Google Scholar
• Jiang YH, Jhang JF, Lee YK, et al. Low-energy shock wave plus intravesical instillation of botulinum toxin a for interstitial cystitis/bladder pain syndrome: pathophysiology and preliminary result of a novel minimally invasive treatment. Biomedicines. 2022;10:396. doi: 10.3390/biomedicines10020396
   PubMed Web of Science ®Google Scholar
• Melville JL, Walker E, Katon W, et al. Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence. Am J Obstet Gynecol. 2002;187(1):80–87. doi: 10.1067/mob.2002.124839
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S574–579.
   PubMed Web of Science ®Google Scholar
• Reynolds WS, Mock S, Zhang X, et al. Somatic syndromes and chronic pain in women with overactive bladder. Neurourol Urodyn. 2017;36(4):1113–1118. doi: 10.1002/nau.23060
   PubMed Web of Science ®Google Scholar
• Yiangou Y, Facer P, Ford A, et al. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001;87:774–779. doi: 10.1046/j.1464-410x.2001.02190.x
   PubMed Web of Science ®Google Scholar
• Avelino A, Cruz C, Nagy I, et al. Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience. 2002;109(4):787–798. doi: 10.1016/S0306-4522(01)00496-1
   PubMed Web of Science ®Google Scholar
• Liu HT, Jiang YH, Kuo HC, et al. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. Plos One. 2013;8(10):e76706. doi: 10.1371/journal.pone.0076706
   PubMed Web of Science ®Google Scholar
• Grundy L, Erickson A, Brierley SM. Visceral pain. Annu Rev Physiol. 2019;81(1):261–284. doi: 10.1146/annurev-physiol-020518-114525
   PubMedGoogle Scholar
• Goldstein HB, Safaeian P, Garrod K, et al. Depression, abuse and its relationship to interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(12):1683–1686. doi: 10.1007/s00192-008-0712-x
   PubMed Web of Science ®Google Scholar
• Persson R, Wensaas KA, Hanevik K, et al. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC Gastroenterol. 2015;5:66. doi: 10.1186/s12876-015-0296-0
   Google Scholar
• But I, Pakiž M, Rakić S. Overactive bladder symptoms and uterine adenomyosis–is there any connection? Eur J Obstet Gynecol Reprod Biol. 2011;156:109–112. doi: 10.1016/j.ejogrb.2010.12.032
   PubMed Web of Science ®Google Scholar
• Grundy L, Harrington AM, Castro J, et al. Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction. JCI Insight. 2018;3(19):e121841. doi: 10.1172/jci.insight.121841
   PubMed Web of Science ®Google Scholar
• Hubeaux K, Deffieux X, Raibaut P, et al. Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome. Neurourol Urodyn. 2011;30(8):1467–1472. doi: 10.1002/nau.21154
   PubMed Web of Science ®Google Scholar
• Kaufman MR, Chang-Kit L, Raj SR, et al. Overactive bladder and autonomic dysfunction: lower urinary tract symptoms in females with postural tachycardia syndrome. Neurourol Urodyn. 2017;36(3):610–613. doi: 10.1002/nau.22971
   PubMed Web of Science ®Google Scholar
• Demir AD, Gursoy AE, Goknar N, et al. Evaluation of autonomic nervous system function in children with overactive bladder syndrome. Neurourol Urodyn. 2017;36(3):673–676. doi: 10.1002/nau.22993
   PubMed Web of Science ®Google Scholar
• Chuang FC, Liu HT, Wang LY, et al. Overactive bladder changes with time: a 5-year longitudinal follow up of changes in overactive bladder symptoms, urodynamic studies and urinary nerve growth factor levels. J Urol. 2014;192(2):458–463. doi: 10.1016/j.juro.2014.02.091
   PubMed Web of Science ®Google Scholar
• Bai J, Tian Y, Wang Y, et al. Physical and rehabilitation therapy for overactive bladder in women: a systematic review and meta-analysis. Int J Clin Pract. 2023;2023:6758454. doi: 10.1155/2023/6758454
   PubMed Web of Science ®Google Scholar
• Hsu LN, Hu JC, Chen PY, et al. Metabolic syndrome and overactive bladder syndrome may share common pathophysiologies. Biomedicines. 2022;10(8):1957. doi: 10.3390/biomedicines10081957
   PubMed Web of Science ®Google Scholar
• Elbaset MA, Taha DE, Sharaf DE, et al. Obesity and overactive bladder: is it a matter of body weight, fat distribution or function? A preliminary results. Urology. 2020;143:91–96. doi: 10.1016/j.urology.2020.04.115
   PubMed Web of Science ®Google Scholar
• Contreras-Sanz A, Krska L, Balachandran AA, et al. Altered urothelial ATP signaling in a major subset of human overactive bladder patients with pyuria. Am J Physiol Renal Physiol. 2016;311(4):F805–F816. doi: 10.1152/ajprenal.00339.2015
   PubMed Web of Science ®Google Scholar
• Gill K, Kang R, Sathiananthamoorthy S, et al. A blinded observational cohort study of the microbiological ecology associated with pyuria and overactive bladder symptoms. Int Urogynecol J. 2018;29(10):1493–1500. doi: 10.1007/s00192-018-3558-x
   PubMed Web of Science ®Google Scholar
• Ke QS, Lee CL, Kuo HC. Recurrent urinary tract infection in women and overactive bladder - is there a relationship? Tzu Chi Med J. 2021;33:13–21. doi: 10.4103/tcmj.tcmj_38_20
   PubMed Web of Science ®Google Scholar
• Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010;16(11):1267–1276. doi: 10.1038/nm.2234
   PubMed Web of Science ®Google Scholar
• Tyagi P, Tyagi V, Qu X, et al. Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. Am J Physiol Renal Physiol. 2016;311:F548–554. doi: 10.1152/ajprenal.00213.2016
   PubMed Web of Science ®Google Scholar
• Liu P, Li Y, Shi B, et al. Comparison of different types of therapy for overactive bladder: a systematic review and network meta-analysis. Front Med. 2022;9:1014291. doi: 10.3389/fmed.2022.1014291
   Web of Science ®Google Scholar
• Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–256. doi: 10.1016/j.eururo.2013.04.001
   PubMed Web of Science ®Google Scholar
• Zillioux J, Slopnick EA, Vasavada SP. Third-line therapy for overactive bladder in the elderly: nuances and considerations. Neurourol Urodyn. 2022;41(8):1967–1974. doi: 10.1002/nau.24965
   PubMed Web of Science ®Google Scholar
• Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189(5):1804–1810. doi: 10.1016/j.juro.2012.11.089
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49(4):644–650. doi: 10.1016/j.eururo.2005.12.010
   PubMed Web of Science ®Google Scholar
• Cruz F. Targets for botulinum toxin in the lower urinary tract. Neurourol Urodyn. 2014;33(1):31–38. doi: 10.1002/nau.22445
   PubMed Web of Science ®Google Scholar
• Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin a. Science. 2006;312(5773):592–596. doi: 10.1126/science.1123654
   PubMed Web of Science ®Google Scholar
• Smith CP, Gangitano DA, Munoz A, et al. Botulinum toxin type a normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int. 2008;52(6):1068–1075. doi: 10.1016/j.neuint.2007.11.006
   PubMed Web of Science ®Google Scholar
• Kanai A, Zabbarova I, Oefelein M, et al. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn. 2012;31(3):300–308. doi: 10.1002/nau.21246
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Priefert J, Knispel HH, et al. Botulinum toxin a detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study. Urology. 2013;81(5):1052–1057. doi: 10.1016/j.urology.2012.12.021
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–2422. doi: 10.1016/j.juro.2010.08.021
   PubMed Web of Science ®Google Scholar
• Kuo HC. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin a injection for idiopathic detrusor overactivity. Neurourol Urodyn. 2011;30(8):1497–1502. doi: 10.1002/nau.21132
   PubMed Web of Science ®Google Scholar
• Anger JT, Weinberg A, Suttorp MJ, et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol. 2010;183(6):2258–2264. doi: 10.1016/j.juro.2010.02.009
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Auerbach S, Ginsberg D, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–157. doi: 10.1016/j.eururo.2012.03.005
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–2193. doi: 10.1016/j.juro.2012.12.022
   PubMed Web of Science ®Google Scholar
• Mohee A, Khan A, Harris N, et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106–113. doi: 10.1111/j.1464-410X.2012.11282.x
   PubMedGoogle Scholar
• Cui Y, Zhou X, Zong H, et al. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis. Neurourol Urodyn. 2015;34(5):413–419. doi: 10.1002/nau.22598
   PubMed Web of Science ®Google Scholar
• Dowson C, Watkins J, Khan MS, et al. Repeated botulinum toxin type a injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61(4):834–839. doi: 10.1016/j.eururo.2011.12.011
   PubMed Web of Science ®Google Scholar
• Reynolds WS, Suskind AM, Anger JT, et al. Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: multi-institutional collaboration from the SUFU research network. Neurourol Urodyn. 2022;41:662–671. doi: 10.1002/nau.24871
   PubMed Web of Science ®Google Scholar
• Martin S, Zillioux J, Goldman HB, et al. Impact of duration of antibiotic prophylaxis on incidence of UTI after onabotulinumtoxinA injection. Urology. 2022;166:140–145. doi: 10.1016/j.urology.2022.05.003
   PubMed Web of Science ®Google Scholar
• Guirguis Hanna M, Bradley M, Zyczynski H, et al. The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA-A secondary analysis. Neurourol Urodyn. 2023;42:1238–1244. doi: 10.1002/nau.25191
   PubMed Web of Science ®Google Scholar
• Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007;178(4 Pt 1):1359–1363. doi: 10.1016/j.juro.2007.05.136
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol. 2010;58(6):919–926. doi: 10.1016/j.eururo.2010.09.007
   PubMed Web of Science ®Google Scholar
• Ou YC, Kao YL, Ho YH, et al. Intravesical injection of botulinum toxin type a in patients with refractory overactive bladder-results between young and elderly populations, and factors associated with unfavorable outcomes. Toxins (Basel). 2023;15:95. doi: 10.3390/toxins15020095
   PubMed Web of Science ®Google Scholar
• Hu JC, Hsu LN, Lee WC, et al. Role of urological botulinum toxin-A injection for overactive bladder and voiding dysfunction in patients with Parkinson’s disease or post-stroke. Toxins (Basel). 2023;15(2):166. doi: 10.3390/toxins15020166
   PubMed Web of Science ®Google Scholar
• Lee HY, Kuo HC. Intravesical injection of botulinum toxin type a in men without bladder outlet obstruction and post-deobstructive prostate surgery. Toxins (Basel). 2023;15(3):221. doi: 10.3390/toxins15030221
   PubMed Web of Science ®Google Scholar
• Wang CC, Lee CL, Hwang YT, et al. Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. Low Urin Tract Symptoms. 2021;13:440–447. doi: 10.1111/luts.12384
   PubMed Web of Science ®Google Scholar
• Ciofu I, Ceausu I, Chirca NM, et al. Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity. Am J Ther. 2022;29:e507–e511. doi: 10.1097/MJT.0000000000001531
   PubMed Web of Science ®Google Scholar
• Chermansky CJ, Richter HE, Jacoby K, et al. Intravesical instillation of onabotulinumtoxinA in the treatment of refractory overactive bladder in participants with urinary incontinence. J Urol. 2022;208(4):855–862. doi: 10.1097/JU.0000000000002800
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tyagi P, Huang CC, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin a delivery using liposomes. J Urol. 2009;182(2):786–792. doi: 10.1016/j.juro.2009.03.083
   PubMed Web of Science ®Google Scholar
• Hung FC, Kuo HC. Liposome-encapsulated botulinum toxin a in treatment of functional bladder disorders. Toxins (Basel). 2022;14(12):838. doi: 10.3390/toxins14120838
   PubMed Web of Science ®Google Scholar
• Liu HT, Chen SH, Chancellor MB, et al. Presence of cleaved synaptosomal-associated protein-25 and decrease of purinergic receptors P2X3 in the bladder urothelium influence efficacy of botulinum toxin treatment for overactive bladder syndrome. Plos One. 2015;10(8):e0134803. doi: 10.1371/journal.pone.0134803
   PubMed Web of Science ®Google Scholar
• Chuang YC, Kaufmann JH, Chancellor DD, et al. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol. 2014;192(6):1743–1749. doi: 10.1016/j.juro.2014.07.008
   PubMed Web of Science ®Google Scholar
• Lu JH, Chueh KS, Chuang SM, et al. Low intensity extracorporeal shock wave therapy as a potential treatment for overactive bladder syndrome. Biology. 2021;10(6):540. doi: 10.3390/biology10060540
   PubMedGoogle Scholar
• Nageib M, Zahran MH, El-Hefnawy AS, et al. Low energy shock wave-delivered intravesical botulinum neurotoxin-A potentiates antioxidant genes and inhibits proinflammatory cytokines in rat model of overactive bladder. Neurourol Urodyn. 2020;39(8):2447–2454. doi: 10.1002/nau.24511
   PubMed Web of Science ®Google Scholar
• Sokolakis I, Pyrgidis N, Neisius A, et al. The effect of low-intensity shockwave therapy on non-neurogenic lower urinary tract symptoms: a systematic review and meta-analysis of preclinical and clinical sstudies. Eur Urol Focus. 2022;8:840–850. doi: 10.1016/j.euf.2021.04.021
   PubMedGoogle Scholar
• Krhut J, Navratilova M, Sykora R, et al. Intravesical instillation of onabotulinum toxin a embedded in inert hydrogel in the treatment of idiopathic overactive bladder: a double-blind randomized pilot study. Scand J Urol. 2016;50(3):200–205. doi: 10.3109/21681805.2015.1121406
   PubMed Web of Science ®Google Scholar
• Fry CH, Chakrabarty B, Hashitani H, et al. New targets for overactive bladder-ICI-RS 2109. Neurourol Urodyn. 2020;39(Suppl 3):S113–S121. doi: 10.1002/nau.24228
   PubMedGoogle Scholar